1/14
07:11 pm
cadl
Loss-Making Candel Therapeutics, Inc. (NASDAQ:CADL) Expected To Breakeven In The Medium-Term [Yahoo! Finance]
Medium
Report
Loss-Making Candel Therapeutics, Inc. (NASDAQ:CADL) Expected To Breakeven In The Medium-Term [Yahoo! Finance]
12/8
09:00 am
cadl
Candel Therapeutics (NASDAQ:CADL) had its "overweight" rating reaffirmed by analysts at Stephens. They now have a $15.00 price target on the stock.
Low
Report
Candel Therapeutics (NASDAQ:CADL) had its "overweight" rating reaffirmed by analysts at Stephens. They now have a $15.00 price target on the stock.
11/17
04:41 pm
cadl
Candel Therapeutics to Host Virtual R&D Event on December 5, 2025 [Yahoo! Finance]
Low
Report
Candel Therapeutics to Host Virtual R&D Event on December 5, 2025 [Yahoo! Finance]
11/17
04:05 pm
cadl
Candel Therapeutics to Host Virtual R&D Event on December 5, 2025
Low
Report
Candel Therapeutics to Host Virtual R&D Event on December 5, 2025
11/15
01:42 am
cadl
Candel Therapeutics (NASDAQ:CADL) was downgraded by analysts at
Wall Str
Low
Report
Candel Therapeutics (NASDAQ:CADL) was downgraded by analysts at
Wall Str
11/14
03:09 pm
cadl
Candel Therapeutics (NASDAQ:CADL) had its price target lowered by analysts at Citigroup Inc. from $25.00 to $24.00. They now have a "buy" rating on the stock.
Low
Report
Candel Therapeutics (NASDAQ:CADL) had its price target lowered by analysts at Citigroup Inc. from $25.00 to $24.00. They now have a "buy" rating on the stock.
11/13
12:28 pm
cadl
Candel Therapeutics GAAP EPS of -$0.21 misses by $0.03 [Seeking Alpha]
Medium
Report
Candel Therapeutics GAAP EPS of -$0.21 misses by $0.03 [Seeking Alpha]
11/13
08:25 am
cadl
Candel Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
Medium
Report
Candel Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
11/4
09:00 am
cadl
Candel Therapeutics Showcases Immunotherapy Leadership at SITC 2025, Demonstrating Integration of Clinical Innovation, Multi-Omics, and Artificial Intelligence to Advance Next-Generation Immunotherapies in Solid Tumors
Low
Report
Candel Therapeutics Showcases Immunotherapy Leadership at SITC 2025, Demonstrating Integration of Clinical Innovation, Multi-Omics, and Artificial Intelligence to Advance Next-Generation Immunotherapies in Solid Tumors
11/3
08:05 am
cadl
Candel Therapeutics to Present at Jefferies Global Healthcare Conference in London
Medium
Report
Candel Therapeutics to Present at Jefferies Global Healthcare Conference in London
10/27
05:02 pm
cadl
Candel Therapeutics (NASDAQ:CADL) is now covered by analysts at Stephens. They set an "overweight" rating on the stock.
Low
Report
Candel Therapeutics (NASDAQ:CADL) is now covered by analysts at Stephens. They set an "overweight" rating on the stock.